Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and DRG oncology experts’ assumptions.

Key Benefits:

  • Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
  • Drill down into physicians’ treatment sequences and understand who to position against or how to defend share.
  • Identify untapped treatment scenarios and key competitors to aid trial design.
  • Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.
  • Discover untapped populations to expand product share and drive strategic decisions.

Questions Answered:

  • Where is my product positioned vs. competitors’ in the treatment journey?
  • What are physicians’ most frequent treatment sequences—who is benefiting, and how can I defend my asset’s share and position?
  • What are the market-relevant treatment scenarios according to oncology experts?
  • How can I optimize trial design and ensure a competitive edge for my pipeline asset?

Related Reports

Colorectal Cancer - Landscape & Forecast - Disease Landscape & Forecast

Chemotherapy remains the dominant cornerstone of colorectal cancer treatment and is prescribed with angiogenesis or EGFR inhibitors in the meta...

View Details

Colorectal Cancer | Disease Landscape and Forecast | G7 | 2020

Targeted therapies and various biomarkers (e.g., RAS, BRAF, MSI-H,dMMR) play an important role in the treatment of colorectal cancer. Treatment is becoming increasingly segmented...

View Details

Colorectal Cancer - Geographic Focus: China - Colorectal Cancer - China In-Depth (China)

Colorectal cancer, a major public health concern in China, is expected to become the second-most-common form of cancer there by 2029, behind only lung cancer. The treatment of metastatic colorectal...

View Details

Colorectal Cancer - Unmet Need - Detailed, Expanded Analysis (US/EU) Previously Treated RAS And BRAF Mutation-Positive Metastatic Colorectal Cancer

This Unmet Need report focuses on the treatment of previously treated RAS and BRAF  mutation-positive metastatic colorectal cancer. Currently, the NCCN guidelines and treatme...

View Details